From: Liver transplantation in adult polycystic liver disease: the Ontario experience
Variable | Total | Male | Female |
---|---|---|---|
Number of Transplants | 51 (100%) | 8 (16%) | 43 (84%) |
Median age* | 54 (46–59) | 62 (59–64) | 52 (45–56) |
Median Waitlist (months) | 9.8 (5.5–18.7) | 10.2 (7.4–14.1) | 9.5 (5–18.8) |
Median MELD score at time of transplant | 13 (7–22) | 22 (17–22) | 10 (6–21) |
Median (years) follow up | 6.3 (12.5) | 2.9 (2.2–4.1) | 8 (3–13.8) |
Orthotopic Liver transplant | 46 (90.1%) | 8 (15.6%) | 38 (74.5%) |
Living donor | 5 (9.8%) | 0 (0%) | 5 (9.8%) |
Liver transplant alone | 29 (56.8%) | 1 (1.9%) | 28 (54.9%) |
Kidney first then liver transplant | 15 (29.4%) | 3 (5.8%) | 12 (23.5%) |
Simultaneous Liver-Kidney transplant (SLK) | 7 (13.7%) | 4 (7.8%) | 3 (5.8%) |
Median Creatinine \((\upmu\) mol) | 101 (80–319) | 426 (237–485) | 91 (73–184) |
Median Hemoglobin (g/L) | 116(109–126) | 118 (113–127) | 116 (109–127) |
Median platelet (109/L)* | 189 (130–239) | 189 (118– 203) | 193 (132–240) |
Median Bilirubin \(\upmu\) mol* | 10 (8–14) | 10 (9–11) | 10 (7–14) |
Median INR* | 1.1 (1–1.2) | 1.2 (1.15–1.2) | 1.1 (1–1.2) |
Median Albumin (g/L)* | 40 (35–43) | 36 (33–40) | 40 (35–43) |
Death | 4 (7.8%) | 1 (1.9%) | 3 (5.8%) |